Key facts
- This page summarizes ARMISTICE CAPITAL, LLC's Form 4 filing for EYEGATE PHARMACEUTICALS INC (KPRX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Aug 2021, 17:09.
ARMISTICE CAPITAL, LLC - 30 Jul 2021 Form 4 Insider Report for EYEGATE PHARMACEUTICALS INC (KPRX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- KPRX
- Reported as of
- 30 Jul 2021
- Net transaction value
- -$646,608
- SEC form
- 4
- Accepted by SEC
- 03 Aug 2021, 17:09:33 UTC
- Prior SEC filing
- 29 Jul 2021
- Next SEC filing
- 06 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- ARMISTICE CAPITAL, LLC by /s/ Steven Boyd, Managing Member
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ARMISTICE CAPITAL, LLC filed Form 4 for EYEGATE PHARMACEUTICALS INC (KPRX) on 03 Aug 2021.
Change
- Previous filing in this sequence was filed on 29 Jul 2021.
- Current net transaction value: -$646,608.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KPRX
transaction
Common Stock
Sale
- Transaction value
- $183,562
- Shares
- -68,188
- Change %
- -6.5%
- Price
- $2.69
- Shares after
- 977,775
- Date
- 30 Jul 2021
- Ownership
- See Footnote
- Footnotes
- F1, F2
KPRX
transaction
Common Stock
Sale
- Transaction value
- $463,046
- Shares
- -192,775
- Change %
- -20%
- Price
- $2.40
- Shares after
- 785,000
- Date
- 02 Aug 2021
- Ownership
- See Footnote
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reported securities of EyeGate Pharmaceuticals, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.6145 to $2.7604, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.3595 to $2.5144, inclusive.